Dermatologic aspects of thyroid disease

Clinics in Dermatology

Volumn 24, Issue 4, 2006, Pages 247-255

  Burman, Kenneth D ^a,b   McKinley Grant, Lynn ^a,c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CORTICOSTEROID; IODINE 123; IODINE 131; LEVOTHYROXINE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; TECHNETIUM 99M; THIAMAZOLE; THYROID HORMONE;

ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW SUPPRESSION; CELL DAMAGE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ERUPTION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER TOXICITY; MYXEDEMA; PRIORITY JOURNAL; SKIN MANIFESTATION; T LYMPHOCYTE; THYROID CANCER; THYROID HORMONE BLOOD LEVEL; THYROIDECTOMY;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; HYPOTHYROIDISM; SKIN DISEASES; T-LYMPHOCYTES; THYROID DISEASES; THYROID NEOPLASMS;

EID: 33745567574     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2006.04.010     Document Type: Article

References (103)

1. Jabbour S.A. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 4 (2003) 315-331
2. Leonhardt JM, Heymann WR. Thyroid disease and the skin. Dermatol Clin 2002;20:473-81, vii.
3. Burman K. Hyperthyroidism, Chapter 41. In: Becker K.A. (Ed). Principles and practice of endocrinology and metabolism. 2nd ed. (1995), J.B. Lippincott, Philadelphia (Pa) 367-385
4. Weiss R.E., Hayashi Y., Nagaya T., et al. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor. [see comments]. J Clin Endocrinol Metab 81 (1996) 4196-4203
5. Mazzaferri E.L., and Surks M.I. Recognizing the faces of hypothyroidism. Hosp Pract (Off Ed) 34 (1999) 93-96
6. Col N.F., Surks M.I., and Daniels G.H. Subclinical thyroid disease: clinical applications. JAMA 291 (2004) 239-243
7. Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 (2004) 228-238
8. Burman K.D., and Cooper D.S. The diagnostic evaluation and management of hyperthyroidism due to Graves' disease, toxic nodules and toxic multinodular goiter. In: Cooper D.S. (Ed) (2001), Marcel Dekker, Inc, New York 33-92
9. Lu R., Burman K.D., and Jonklaas J. Transient Graves' hyperthyroidism during pregnancy in a patient with Hashimoto's hypothyroidism. Thyroid 15 (2005) 725-729
10. Solomon B.L., Wartofsky L., and Burman K.D. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81 (1996) 333-339
11. Niepomniszcze H., and Amad R.H. Skin disorders and thyroid diseases. J Endocrinol Invest 24 (2001) 628-638
12. Rotella C.M., Alvarez F., Kohn L.D., and Toccafondi R. Graves' autoantibodies to extrathyroidal TSH receptor: their role in ophthalmopathy and pretibial myxedema. Acta Endocrinol Suppl (Copenh) 281 (1987) 344-347
13. Chavis P.S. Thyroid and the eye. Curr Opin Ophthalmol 13 (2002) 352-356
14. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6 (2005) 295-309
15. Fatourechi V., Ahmed D.D., and Schwartz K.M. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab 87 (2002) 5435-5441
16. Fatourechi V., Aniszewski J.P., Fatourechi G.Z., Atkinson E.J., and Jacobsen S.J. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab 88 (2003) 2100-2105
17. De Bruin T.W., L.E., and Brown R.S. Heterogeneity of TSH receptor-binding antibodies in Hashimoto's thyroiditis and Graves' disease. Am J Med Sci 299 (1990) 291-297
18. 2 by recognizing specific epitopes on thyrotropin receptor. J Clin Endocrinol Metab 84 (1999) 3283-3292
19. Bahn R.S. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest 27 (2004) 216-220
20. Bahn R.S., and Heufelder A.E. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 329 (1993) 1468-1475
21. Kohar Y.M., and Tan K.C. Preradial myxedema: a case report. Ann Acad Med Singapore 25 (1996) 281-282
22. Wortsman J., Dietrich J., Traycoff R.B., and Stone S. Preradial myxedema in thyroid disease. Arch Dermatol 117 (1981) 635-638
23. Evans T.C. Thyroid disease. Prim Care 30 (2003) 625-640
24. Leovey A., Sztojka I., Paragh G., and Mohacsi A. Atypical clinical features of hypo- and hyperthyroidism in elderly age. Ther Hung 39 (1991) 167-174
25. Stathatos N., and Wartofsky L. The euthyroid sick syndrome: is there a physiologic rationale for thyroid hormone treatment?. J Endocrinol Invest 26 (2003) 1174-1179
26. Wartofsky L., and Burman K.D. Alterations in thyroid function in patients with systemic illness: the euthyroid sick syndrome. Endocr Rev 3 (1982) 164-217
27. Weetman A.P., et al. The production and characterization of thyroid-derived T-cell lines in Graves' disease and Hashimoto's thyroiditis. Clin Immunol Immunopathol 39 (1986) 139-150
28. Endo T., Kogai T., Nakazato M., et al. Autoantibody against Na+/I- symporter in the sera of patients with autoimmune thyroid disease. Biochem Biophys Res Commun 224 (1996) 92-95
29. Jansson R., Totterman T.H., Sallstrom J., and Dahlberg P. Thyroid-infiltrating T lymphocyte subsets in Hashimoto's thyroiditis. J Clin Endocrinol Metab 56 (1983) 1164-1168
30. Kohn L.D., Suzuki K., Hoffman W.H., et al. Characterization of monoclonal thyroid-stimulating and thyrotropin binding-inhibiting autoantibodies from a Hashimoto's patient whose children had intrauterine and neonatal thyroid disease. J Clin Endocrinol Metab 82 (1997) 3998-4009
31. Ai J., Leonhardt J.M., and Heymann W.R. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol 48 (2003) 641-659 [quiz 660-2]
32. Akamizu T., Kohn L.D., Hiratani H., et al. Hashimoto's thyroiditis with heterogeneous antithyrotropin receptor antibodies: unique epitopes may contribute to the regulation of thyroid function by the antibodies. J Clin Endocrinol Metab 85 (2000) 2116-2121
33. Wang S.A., Rahemtullah A., Faquin W.C., et al. Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol (2005)
34. Slatosky J., Shipton B., and Wahba H. Thyroiditis: differential diagnosis and management. Am Fam Physician 61 (2000) 1047-1052
35. Lucas A., Pizarro E., Granada M.L., et al. Postpartum thyroiditis: long-term follow-up. Thyroid 15 (2005) 1177-1181
36. Stagnaro-Green A. Recognizing, understanding, and treating postpartum thyroiditis. Endocrinol Metab Clin North Am 2000;29:417-30, ix.
37. Stagnaro-Green A. Clinical review 152: postpartum thyroiditis. J Clin Endocrinol Metab 87 (2002) 4042-4047
38. Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab 18 (2004) 303-316
39. Stagnaro-Green A., and Glinoer D. Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab 18 (2004) 167-181
40. Bartley G.B. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 92 (1994) 477-588
41. Bartley G.B., Fatourechi V., Kadrmas E.F., et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 121 (1996) 284-290
42. Lu R., et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid 9 (1999) 297-303
43. K.D. Burman. Thyroid disease and osteoporosis. Hosp Pract (Off Ed) 1997;32:71-3, 78-85; discussion 85-6.
44. Burch H.B., and Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14 (1993) 747-793 [Review]
45. Higuchi R., Kumagai T., Kobayashi M., et al. Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease. Pediatrics 107 (2001) E57
46. Grant D.B., Smith I., Fuggle P.W., Tokar S., and Chapple J. Congenital hypothyroidism detected by neonatal screening: relationship between biochemical severity and early clinical features. Arch Dis Child 67 (1992) 87-90
47. LaFranchi S. Congenital hypothyroidism: etiologies, diagnosis, and management. Thyroid 9 (1999) 735-740
48. Podkrajsek K.T., Bratanic N., Krzisnik C., and Battelino T. Autoimmune regulator-1 messenger ribonucleic acid analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. J Clin Endocrinol Metab 90 (2005) 4930-4935
49. Burman K.D. Is long-term levothyroxine therapy safe?. Arch Intern Med 150 (1990) 2010-2013
50. Ain K.B., Pucino F., Shiver T.M., and Banks S.M. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid 3 (1993) 82-85
51. Hennessey J.V., Evaul J.E., Tseng Y.C., Burman K.D., and Wartofsky L. l-Thyroxine dosage: a reevaluation of therapy with contemporary preparations. Ann Intern Med 105 (1986) 11-15
52. Dickey R.A., Wartofsky L., and Feld S. Optimal thyrotropin level: normal ranges and reference intervals are not equivalent. Thyroid 15 (2005) 1035-1039
53. Wartofsky L. Update in endocrinology. Ann Intern Med 143 (2005) 673-682
54. Wartofsky L. Levothyroxine therapy for hypothyroidism: should we abandon conservative dosage titration?. Arch Intern Med 165 (2005) 1683-1684
55. Wartofsky L., and Dickey R.A. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90 (2005) 5483-5488
56. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 1433-1441
57. Mazzaferri E.L., and Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 9 (2002) 227-247
58. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 (2003) 409-416 [discussion 416]
59. Ain K.B. Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14 (2000) 615-629
60. Pedersen R.K., and Pedersen N.T. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. Histopathology 28 (1996) 25-32
61. Solomon B.L., et al. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81 (1996) 333-339
62. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12 (2002) 583-590
63. Burman K.D., Ringel M.D., and Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am 25 (1996) 49-68
64. Burningham A.R., Krishnan J., Davidson B.J., Ringel M.D., and Burman K.D. Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg 132 (2005) 840-844
65. Newkirk K.A., Ringel M.D., Jelinek J., et al. Ultrasound-guided fine-needle aspiration and thyroid disease. Otolaryngol Head Neck Surg 123 (2000) 700-705
66. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. J Clin Endocrinol Metab 87 (2002) 1486-1489
67. Alwaheeb S., Ghazarian D., Boerner S.L., and Asa S.L. Cutaneous manifestations of thyroid cancer: a report of four cases and review of the literature. J Clin Pathol 57 (2004) 435-438
68. Avram A.M., Gielczyk R., Su L., Vine A.K., and Sisson J.C. Choroidal and skin metastases from papillary thyroid cancer: case and a review of the literature. J Clin Endocrinol Metab 89 (2004) 5303-5307
69. Azoulay S., Adem C., Pelletier F.L., et al. Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin. J Cutan Pathol 32 (2005) 561-566
70. Kumar P.V., Monabati A., Tabei S.Z., et al. Metastatic follicular thyroid carcinoma diagnosed by fine needle aspiration cytology: a report of 3 cases. Acta Cytol 49 (2005) 177-180
71. Mahalingam M., and Bhawan J. Metastatic papillary carcinoma of the thyroid. J Cutan Pathol 31 (2004) 509-512
72. Mishra A., Samant D.D., Krishnani N., and Saroj K.M. Unusual distant metastases from papillary thyroid carcinoma. J Assoc Physicians India 50 (2002) 1338
73. Angerpointner T.A. Management of patients with hereditary medullary thyroid carcinoma. J Pediatr Surg 40 (2005) 1214
74. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol 17 (2005) 7-12
75. Dannenberg H., Komminoth P., Dinjens W.N., Speel E.J., and de Krijger R.R. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocr Pathol 14 (2003) 329-350
76. de Krijger R.R. Endocrine tumor syndromes in infancy and childhood. Endocr Pathol 15 (2004) 223-226
77. Fitze G. Management of patients with hereditary medullary thyroid carcinoma. Eur J Pediatr Surg 14 (2004) 375-383
78. Jimenez C., and Gagel R.F. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm IGF Res 14 Suppl A (2004) S150-S157
79. Koch C.A. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer 4 (2005) 3-7
80. Massoll N., and Mazzaferri E.L. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med 24 (2004) 49-83
81. Brauckhoff M., Gimm O., Weiss C.L., et al. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 28 (2004) 1305-1311
82. Chang A., Chan W.F., Lo C.Y., and Lam K.S. Multiple endocrine neoplasia type 2B in a Chinese patient. Hong Kong Med J 10 (2004) 206-209
83. Kameyama K., Okinaga H., and Takami H. Clinical manifestations of familial medullary thyroid carcinoma. Biomed Pharmacother 58 (2004) 348-350
84. Zhang Y.F., Hong J., Zhao Y.J., et al. Multiple endocrine neoplasia type 2B caused by a single point mutation in RET proto-oncogene in a Chinese patient. Chin Med J (Engl) 117 (2004) 1262-1264
85. Holloway K.B., and Flowers F.P. Multiple endocrine neoplasia 2B (MEN 2B)/MEN 3. Dermatol Clin 13 (1995) 99-103
86. Lora M.S., Waguespack S.G., Moley J.F., and Walvoord E.C. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases. J Clin Endocrinol Metab 90 (2005) 4383-4387
87. Sweetser D.A., Froelick G.J., Matsumoto A.M., et al. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice. Oncogene 18 (1999) 877-886
88. Bauer A.J., and Stratakis C.A. The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet 42 (2005) 801-810
89. Bourdeau I., Lacroix A., Schurch W., et al. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. J Clin Endocrinol Metab 88 (2003) 3931-3937
90. Robinson-White A., Hundley T.R., Shiferaw M., et al. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet 12 (2003) 1475-1484
91. Sandrini F., and Stratakis C. Clinical and molecular genetics of primary pigmented nodular adrenocortical disease. Arq Bras Endocrinol Metabol 48 (2004) 637-641
92. Stratakis C.A., Matyakhina L., Courkoutsakis N., et al. Pathology and molecular genetics of the pituitary gland in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas' (Carney complex). Front Horm Res 32 (2004) 253-264
93. McDonnell JK. Cardiac disease and the skin. Dermatol Clin 2002;20:503-11, vii.
94. Kato N., Kimura K., Sugawara H., et al. Germline mutation of the PTEN gene in a Japanese patient with Cowden's disease. Int J Oncol 18 (2001) 1017-1022
95. Reifenberger J., Rauch L., Beckmann M.W., et al. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol 148 (2003) 1040-1046
96. Wirtzfeld D.A., Petrelli N.J., and Rodriguez-Bigas M.A. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations. Ann Surg Oncol 8 (2001) 319-327
97. Eng C. Molecular basis of thyroid cancer: molecular basis of thyroid cancer. Thyroid 15 (2005) 1109
98. Allen B.S., Fitch M.H., and Smith Jr. J.G. Multiple hamartoma syndrome. A report of a new case with associated carcinoma of the uterine cervix and angioid streaks of the eyes. J Am Acad Dermatol 2 (1980) 303-308
99. Prabhu S.S., Aldape K.D., Bruner J.M., and Weinberg J.S. Cowden disease with Lhermitte-Duclos disease: case report. Can J Neurol Sci 31 (2004) 542-549
100. Haibach H., et al. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Am J Clin Pathol 97 (1992) 705-712
101. Marsh D.J., Dahia P.L., Caron S., et al. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35 (1998) 881-885
102. Perez-Nunez A., Lagares A., Benitez J., et al. Lhermitte-Duclos disease and Cowden disease: clinical and genetic study in five patients with Lhermitte-Duclos disease and literature review. Acta Neurochir (Wien) 146 (2004) 679-690
103. Burman K., Becker K., Cytryn A., and Goodglick T. Thyroid diseases. In: Korenman S.G. (Ed) (1999), Current Medicine, Inc. Blackwell Publishers, The Atlas of Clinical Endocrinology, Philadelphia